Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin + etoposide with or without atezolizumab in untreated extensive‑stage small cell lung cancer
jRCT2080223248Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Atezolizumab + carboplatin + etoposide with Placebo + carboplatin + etoposide (2 arms). Primary endpoint: Overall survival. Started Jun 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2080223248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223248.